Amgen Stock Takes a Hit as Analyst Downgrades Weigh In
Amgen's stock took a hit today as it closed down nearly 2% amidst analyst downgrades and broader market turmoil. The biopharma giant saw its shares decline by 1.77% in trading, settling at CA$384.33.
The company's market capitalization stands at approximately CA$211.53 billion, a testament to its significant presence in the industry despite current challenges.
HSBC downgraded Amgen from Buy to Hold, lowering its target price from $445 to $425. Analysts pointed out that while the stock has performed well operationally, it is now trading close to its target price, indicating limited near-term upside.
The recent downgrade comes as the biopharma sector faces increased competition and a shift in investor focus towards companies with stronger growth potential.